The prognostic value of the orphan nuclear receptor DAX-1 (NROB1) in node-negative breast cancer

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 443-449

  Zhang, Hui ^a,b   Slewa, Aida ^a   Janssen, Emiel ^a   Skaland, Ivar ^a   Yu, Yinhua ^c,d   Gudlaugsson, Einar ^a   Feng, Weiwei ^d   Kjellevold, Kjell ^a   Søiland, Håvard ^a   Baak, Jan P A ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF TEXAS   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

ApoD; Breast cancer; DAX 1; ER ; Prognosis

Indexed keywords

APOLIPOPROTEIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NUCLEAR RECEPTOR DAX 1;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER MORTALITY; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME INHIBITION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MITOSIS INDEX; MITOSIS RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS D; BREAST NEOPLASMS; DAX-1 ORPHAN NUCLEAR RECEPTOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953251677     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Collins JA, Blake JM and Crosignani PG: Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11: 545-560, 2005. (Pubitemid 41631306)
2. Ing R, Petrakis NL and Ho JH: Unilateral breast-feeding and breast cancer. Lancet 2: 124-127, 1977.
3. Korenman SG: Oestrogen window hypothesis of the aetiology of breast cancer. Lancet 1: 700-701, 1980.
4. Chen H, Lin RJ, Xie W, Wilpitz D and Evans RM: Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98: 675-686, 1999. (Pubitemid 29418958)
5. Zhang H, Thomsen JS, Johansson L, Gustafsson JA and Treuter E: DAX-1 functions as an LXXLL-containing co-repressor for activated estrogen receptors. J Biol Chem 275: 39855-39859, 2000. (Pubitemid 32065755)
6. Muscatelli F, Strom TM, Walker AP, Zanaria E, Recan D, Meindl A, Bardoni B, Guioli S, Zehetner G, Rabl W et al: Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 372: 672-676, 1994.
7. Helguero LA, Hedengran Faulds M, Förster C, Gustafsson JA and Haldosén LA: DAX-1 expression is regulated during mammary epithelial cell differentiation. Endocrinology 147: 3249-3259, 2006. (Pubitemid 43904302)
8. Gurates B, Sebastian S, Yang S, Zhou J, Tamura M, Fang Z, Suzuki T, Sasano H and Bulun SE: WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells. J Clin Endocrinol Metab 87: 4369-4377, 2002.
9. Wang ZJ, Jeffs B, Ito M, Achermann JC, Yu RN, Hales DB and Jameson JL: Aromatase (Cyp19) expression is up-regulated by targeted disruption of Dax1. Proc Natl Acad Sci USA 98: 7988-7993, 2001.
10. Agoulnik IU, Krause WC, Bingman WE, III, Rahman HT, Amrikachi M, Ayala GE and Weigel NL: Repressors of androgen and progesterone receptor action. J Biol Chem 278: 31136-31148, 2003.
11. Helguero LA, Hedengran Faulds M, Forster C, Gustafsson JA and Haldosen LA: DAX-1 expression is regulated during mammary epithelial cell differentiation. Endocrinology 147: 3249-3259, 2006. (Pubitemid 43904302)
12. Conde I, Alfaro JM, Fraile B, Ruiz A, Paniagua R and Arenas MI: DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alpha, ER-beta and androgen receptor status. Breast Cancer Res 6: R140-148, 2004.
13. Harding C, Osundeko O, Tetlow L, Faragher EB, Howell A and Bundred NJ: Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. Br J Cancer 82: 354-360, 2000. (Pubitemid 30045381)
14. Soiland H, Soreide K, Janssen EA, Korner H, Baak JP and Soreide JA: Emerging concepts of apolipoprotein D with possible implications for breast cancer. Cell Oncol 29: 195-209, 2007. (Pubitemid 46855702)
15. Soiland H, Janssen EA, Korner H, Varhaug JE, Skaland I, Gudlaugsson E, Baak JP and Soreide JA: Apolipoprotein D predicts adverse outcome in women ≤70 years with operable breast cancer. Breast Cancer Res Treat 113: 519-528, 2009.
16. Soiland H, Skaland I, Varhaug JE, Korner H, Janssen EA, Gudlaugsson E, Baak JP and Soreide JA: Co-expression of estrogen receptor alpha and apolipoprotein D in node-positive operable breast cancer-possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients. Acta Oncol 48: 514-521, 2009.
17. Histologic Typing of Breast Tumors. 2nd ed. Geneva: World Health Organization, 1981.
18. Ellis IO, Schnitt SJ and Sastre-Garau X: Invasive breast carcinoma. In: Pathology and Genetics of Tumors of the Breast and Female Genital Tract Organs. pp. 18-19, 2003.
19. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
20. Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS, Los J, Peterse HC et al: The Multicenter Morphometric Mammary Carcinoma Project (MMMCP): A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in the Netherlands. Pathol Res Pract 185: 664-670, 1989. (Pubitemid 20076937)
21. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB and Janssen EA: Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23: 5993-6001, 2005.
22. Janssen EA, van Diest PJ, Soiland H, Gudlaugson E, Nysted A, Voorhorst FJ, Vermorken JB, Soreide JA and Baak JP: Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years. Cell Oncol 28: 295-303, 2006. (Pubitemid 44950100)
23. Hodi Z, Chakrabarti J, Ue AH, Ronan JE, Elston CW, Cheung KL, Robertson JF and Ellis IO: The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol 60: 299-302, 2007. (Pubitemid 46447747)
24. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H and Baak JP: Validating the prognostic value of proliferation measured by phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat 114: 39-45, 2009.
25. Zazopoulos E, Lalli E, Stocco DM and Sassone-Corsi P: DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis. Nature 390: 311-315, 1997. (Pubitemid 27513317)
26. Abd-Elaziz M, Akahira J, Moriya T, Suzuki T, Yaegashi N and Sasano H: Nuclear receptor DAX-1 in human common epithelial ovarian carcinoma: an independent prognostic factor of clinical outcome. Cancer Sci 94: 980-985, 2003. (Pubitemid 37508981)
27. Oda T, Tian T, Inoue M, Ikeda J, Qiu Y, Okumura M, Aozasa K and Morii E: Tumorigenic role of orphan nuclear receptor NR0B1 in lung adenocarcinoma. Am J Pathol 175: 1235-1245, 2009.
28. Nakamura Y, Suzuki T, Arai Y and Sasano H: Nuclear receptor DAX1 in human prostate cancer: a novel independent biological modulator. Endocr J 56: 39-44, 2009.
29. Saito S, Ito K, Suzuki T, Utsunomiya H, Akahira J, Sugihashi Y, Niikura H, Okamura K, Yaegashi N and Sasano H: Orphan nuclear receptor DAX-1 in human endometrium and its disorders. Cancer Sci 96: 645-652, 2005. (Pubitemid 41723540)
30. Simard J, Veilleux R, de Launoit Y, Haagensen DE and Labrie F: Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. Cancer Res 51: 4336-4341, 1991.
31. Skaland I, van Diest PJ, Janssen EA, Gudlaugsson E and Baak JP: Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. Hum Pathol 39: 584-590, 2008.